Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia.

There is no fulltext present in this item.

Title:	Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia.
Author(s):	Savonije, J.H.; Groeningen, C.J. van; Broek, W.J.A.A. van den ; Rentinck, M.E.; Corstens, F.H.M. ; Gundy, C.; Giaccone, G.; Marx, J.J.M.
Publication year:	2006
Source:	Cancer Investigation, vol. 24, iss. 6, (2006), pp. 562-566
ISSN:	0735-7907
DOI:	https://doi.org/10.1080/07357900600894757
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/51292
Display more details
Subject:	N4i 1: Pathogenesis and modulation of inflammation UMCN 5.1: Genetic defects of metabolism
Organization:	Cell Biology (UMC) Nuclear Medicine Clinical Chemistry
Journal title:	Cancer Investigation
Volume:	vol. 24
Issue:	iss. 6
Page start:	p. 562
Page end:	p. 566
Abstract:	Absorption of a physiological dose of ferrous iron was studied in 18 patients with solid malignancy receiving epoetin therapy for mild chemotherapy-associated anemia. The historical control group consisted of 25 iron replete volunteers (iron absorption 20 +/- 11% in males and 26 +/- 13% in females) and 21 patients with uncomplicated iron deficiency (iron absorption 71 +/- 19%). Iron absorption was increased in the majority of the cancer patients (iron absorption 59 +/- 35%). There were no significant differences in iron absorption between cancer patients who were iron replete or iron deficient according to current clinical practice guidelines (iron deficiency: transferrin saturation < 20% and/or serum ferritin < 100 ng/mL). Red cell iron incorporation was not disturbed in the majority (89%) of patients.